Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma.
Thomas J. George
Consultant or Advisory Role - Regeneron
Research Funding - Bayer; Bristol-Myers Squibb
Alison Marguerite Ivey
No relevant relationships to disclose
Karen Colleen Daily
No relevant relationships to disclose
Long H. Dang
No relevant relationships to disclose
Scott Watson
No relevant relationships to disclose
Renee Granicz
No relevant relationships to disclose
Kevin Tormes
No relevant relationships to disclose
Xiaomin Lu
No relevant relationships to disclose
Chen Liu
No relevant relationships to disclose
Carmen Joseph Allegra
No relevant relationships to disclose
Kevin Behrns
No relevant relationships to disclose
Steven J. Hughes
No relevant relationships to disclose
Olorunseun Olatunji Ogunwobi
No relevant relationships to disclose
Jose Gilberto Trevino
No relevant relationships to disclose